Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients

International Archives of Occupational and Environmental Health

Volumn 81, Issue 3, 2008, Pages 285-293

  Hedmer, Maria ^a   Höglund, Peter ^a   Cavallin Ståhl, Eva ^a   Albin, Maria ^a   Jönsson, Bo A G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antineoplastic drug; Biological monitoring; Breast cancer patients; Cyclophosphamide; Pharmacokinetics; Renal clearance; Risk assessment; Urine flow

Indexed keywords

ATENOLOL; ATORVASTATIN; BETAMETHASONE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FELODIPINE; FLUCONAZOLE; FLUNITRAZEPAM; FLUOROURACIL; LEVOFLOXACIN; LEVOTHYROXINE; LORAZEPAM; MESNA; METOCLOPRAMIDE; NYSTATIN; OMEPRAZOLE; PARACETAMOL; PREDNISOLONE; PROCHLORPERAZINE; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TROPISETRON;

ADULT; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG EXPOSURE; FEMALE; HUMAN; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MICTURITION; TANDEM MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; RISK ASSESSMENT;

EID: 36549020041     PISSN: 03400131     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00420-007-0211-2     Document Type: Article

References (41)

1. Bagley CM Jr, Bostick FW, DeVita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33:226-233
2. Bailey H, Mulcahy RT, Tutsch KD, Rozental JM, Alberti D, Arzoomanian RZ, Tombes MB, Trump DL, Wilding G (1991) A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection. Cancer Res 51:1099-1104
3. Batey MA, Wright JG, Azzabi A, Newell DR, Lind MJ, Calvert AH, Boddy AV (2002) Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer 38:1081-1089
4. Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, Schumacher K, Schweizer E, Kroemer HK (1997) Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism. J Clin Oncol 15:1885-1896
5. Busse D, Busch FW, Schweizer E, Bohnenstengel F, Eichelbaum M, Fischer P, Schumacher K, Aulitzky WE, Kroemer HK (1999) Fractionated administration of high-dose cyclophosphamide: Influence on dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother Pharmacol 43:263-268
6. Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, Grochow LB (1995) Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 55:810-816
7. Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA (1999) Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 56:1427-1432
8. de Jong ME, Huitema ADR, van Dam SM, Rodenhuis S, Beijnen JH (2005) Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. Anticancer Drugs 16:331-336
9. Ensslin AS, Stoll Y, Pethran A, Pfaller A, Rommelt H, Fruhmann G (1994) Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 51:229-233
10. Evelo CT, Bos RP, Peters JG, Henderson PT (1986) Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 58:151-155
11. Hedmer M, Georgiadi A, Rämme Bremberg E, Jönsson BAG, Eksborg S (2005) Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg 49:629-637
12. Hirst M, Tse S, Mills DG, Levin L, White DF (1984) Occupational exposure to cyclophosphamide. Lancet 1:186-188
13. IARC (1981) Monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 26. Some antineoplastic and immunosuppressive agents. International Agency for Research on Cancer, Lyon
14. IARC (1987) Monographs on the evaluation of the carcinogenic risk to humans, suppl 7. Overall evaluation of carcinogenicity: An updating of IARC monographs, vol 1-42. International Agency for Research on Cancer, Lyon
15. Joqueviel C, Martino R, Gilard V, Malet-Martino M, Canal P, Niemeyer U (1998) Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab Dispos 26:418-428
16. Kasel D, Jetter A, Harlfinger S, Gebhardt W, Fuhr U (2004) Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 18:1472-1478
17. Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, Isaacs R, McKeage MJ (2004) Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clin Exp Pharmacol Physiol 31:677-682
18. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M McDonald GB (2004) Cyclophosphamide metabolism is affected by azole antifungals. Blood 103:1557-1559
19. McDevitt JJ, Lees PS, McDiarmid MA (1993) Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 35:57-60
20. Milsted RA, Jarman M (1982) Metabolism of high doses of cyclophosphamide. Cancer Chemother Pharmacol 8:311-313
21. Minoia C, Turci R, Sottani C, Schiavi A, Perbellini L, Angeleri S, Draicchio F, Apostoli P (1998) Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 12:1485-1493
22. Moore MJ (1991) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20:194-208
23. Parkinson A (2001) Biotransformation of xenobiotics. In: Klaassen CD (ed) Casarett and Doull's toxicology: The basic science of poisons 6th edn. McGraw-Hill, New York
24. Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D (2003) Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health 76:5-10
25. Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT (1998) Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 64:289-301
26. Rowland M, Tozer TN (1995) Clinical pharmacokinetics. Concepts and applications. Lippincot, Williams & Wilkins, Philadelphia
27. Roy P, Yo LJ, Crespi CL, Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666
28. Sadagopan N, Cohen L, Roberts B, Collard W, Omer C (2001) Liquid chromatography-tandem mass spectrometric quantification of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. J Chromatogr B Biomed Sci Appl 759:277-284
29. Sannolo N, Miraglia N, Biglietto M, Acampora A, Malorni A (1999) Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry. J Mass Spectrom 34:845-849
30. Schmaus G, Schierl R, Funck S (2002) Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm 59:956-961
31. Sessink PJ, Anzion RB, Van den Broek PH, Bos RP (1992a) Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 14:16-22
32. Sessink PJ, Boer KA, Scheefhals AP, Anzion RB, Bos RP (1992b) Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 64:105-112
33. Sessink PJ, Van de Kerkhof MC, Anzion RB, Noordhoek J, Bos RP (1994) Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environ Health 49:165-169
34. Sessink PJ, Kroese ED, van Kranen HJ, Bos RP (1995) Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 67:317-323
35. Sladek NE (1994) Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In: Powis G (ed) Anticancer drugs: Reactive metabolism and drug interactions. Pergamon Press, Oxford
36. Sorsa M, Anderson D (1996) Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res 355:253-61
37. Sottani C, Turci R, Perbellini L, Minoia C (1998) Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 12:1063-1068
38. Thulin H, Zorcec V, Segerbäck D, Sundwall A, Törnqvist M (1996) Oxazolidonylethyl adducts to hemoglobin and DNA following nornitrogen mustard exposure. Chem Biol Interact 99:263-275
39. Turci R, Sottani C, Ronchi A, Minoia C (2002) Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett 134:57-64
40. Wick C, Slawson MH, Jorgenson JA, Tyler LS (2003) Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm 60:2314-2320
41. Xie HJ (2004) Pharmacogenetic and pharmacokinetic studies of cyclophosphamide. In cell, animal and human. Karolinska Institutet at Karolinska University Hospital, Stockholm